From 903aece7dce781a72ec5793b6b4d784c14b62b62 Mon Sep 17 00:00:00 2001 From: joseph-rickert Date: Fri, 3 Nov 2023 00:17:14 +0000 Subject: [PATCH] =?UTF-8?q?Deploying=20to=20gh-pages=20from=20=20@=203552d?= =?UTF-8?q?21862f476140881dbd134c54439bbac0a5a=20=F0=9F=9A=80?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit --- commontables.html | 1369 +++++++++-------- contributors.html | 6 +- formatting-and-rendering-tables.html | 367 ++--- index.html | 8 +- .../css/open-sans.css | 0 .../open-sans-v36-latin_latin-ext-700.eot | Bin .../open-sans-v36-latin_latin-ext-700.svg | 0 .../open-sans-v36-latin_latin-ext-700.ttf | Bin .../open-sans-v36-latin_latin-ext-700.woff | Bin .../open-sans-v36-latin_latin-ext-700.woff2 | Bin ...pen-sans-v36-latin_latin-ext-700italic.eot | Bin ...pen-sans-v36-latin_latin-ext-700italic.svg | 0 ...pen-sans-v36-latin_latin-ext-700italic.ttf | Bin ...en-sans-v36-latin_latin-ext-700italic.woff | Bin ...n-sans-v36-latin_latin-ext-700italic.woff2 | Bin .../open-sans-v36-latin_latin-ext-italic.eot | Bin .../open-sans-v36-latin_latin-ext-italic.svg | 0 .../open-sans-v36-latin_latin-ext-italic.ttf | Bin .../open-sans-v36-latin_latin-ext-italic.woff | Bin ...open-sans-v36-latin_latin-ext-italic.woff2 | Bin .../open-sans-v36-latin_latin-ext-regular.eot | Bin .../open-sans-v36-latin_latin-ext-regular.svg | 0 .../open-sans-v36-latin_latin-ext-regular.ttf | Bin ...open-sans-v36-latin_latin-ext-regular.woff | Bin ...pen-sans-v36-latin_latin-ext-regular.woff2 | Bin references.html | 14 +- reports/flextable-title-01.docx | Bin 13913 -> 14398 bytes search_index.json | 2 +- tablepkgs.html | 20 +- 29 files changed, 899 insertions(+), 887 deletions(-) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/css/open-sans.css (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700.eot (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700.svg (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700.ttf (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700.woff (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700.woff2 (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700italic.eot (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700italic.svg (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700italic.ttf (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700italic.woff (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-700italic.woff2 (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-italic.eot (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-italic.svg (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-italic.ttf (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-italic.woff (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-italic.woff2 (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-regular.eot (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-regular.svg (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-regular.ttf (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-regular.woff (100%) rename libs/{open-sans-0.3.3 => open-sans-0.3.4}/fonts/open-sans-v36-latin_latin-ext-regular.woff2 (100%) diff --git a/commontables.html b/commontables.html index 73ef368..88b379b 100644 --- a/commontables.html +++ b/commontables.html @@ -6,7 +6,7 @@ Chapter 4 Commonly Used Tables | Tables in Clinical Trials with R - + @@ -23,7 +23,7 @@ - + @@ -55,7 +55,7 @@ - + @@ -1018,21 +1018,21 @@

4.1.3 gtAge (Years) n -134 -134 -132 +134
+134
+132
Mean (SD) -33.8 (6.6) -35.4 (7.9) -35.4 (7.7) +33.8 (6.6)
+35.4 (7.9)
+35.4 (7.7)
Median -33 -35 -35 +33
+35
+35
Min - Max -21 - 50 -21 - 62 -20 - 69 +
21 - 50 +
21 - 62 +
20 - 69 Sex, n (%) @@ -1041,21 +1041,21 @@

4.1.3 gt134 132 F -79 (59.0) -77 (57.5) -66 (50.0) +79 (59.0)
+77 (57.5)
+66 (50.0)
M -51 (38.1) -55 (41.0) -60 (45.5) +51 (38.1)
+55 (41.0)
+60 (45.5)
U -3 (2.2) -2 (1.5) -4 (3.0) +3 (2.2)
+2 (1.5)
+4 (3.0)
UNDIFFERENTIATED -1 (0.7) -0 -2 (1.5) +1 (0.7)
+0
+2 (1.5)
Country, n (%) @@ -1064,41 +1064,41 @@

4.1.3 gt134 132 CHN -74 (55.2) -81 (60.4) -64 (48.5) +74 (55.2)
+81 (60.4)
+64 (48.5)
USA -10 (7.5) -13 (9.7) -17 (12.9) +10 (7.5)
+13 (9.7)
+17 (12.9)
BRA -13 (9.7) -7 (5.2) -10 (7.6) +13 (9.7)
+7 (5.2)
+10 (7.6)
PAK -12 (9.0) -9 (6.7) -10 (7.6) +12 (9.0)
+9 (6.7)
+10 (7.6)
NGA -8 (6.0) -7 (5.2) -11 (8.3) +8 (6.0)
+7 (5.2)
+11 (8.3)
RUS -5 (3.7) -8 (6.0) -6 (4.5) +5 (3.7)
+8 (6.0)
+6 (4.5)
JPN -5 (3.7) -4 (3.0) -9 (6.8) +5 (3.7)
+4 (3.0)
+9 (6.8)
GBR -4 (3.0) -3 (2.2) -2 (1.5) +4 (3.0)
+3 (2.2)
+2 (1.5)
CAN -3 (2.2) -2 (1.5) -3 (2.3) +3 (2.2)
+2 (1.5)
+3 (2.3)
@@ -1156,7 +1156,7 @@

4.1.4 flextable ft -

x.x: Study Subject Data

x.x.x: Demographic Characteristics

Table x.x.x.x: Demographic Characteristics - Full Analysis Set

A: Drug X
(N=134)

B: Placebo
(N=134)

C: Combination
(N=132)

Age

 Mean (SD)

33.8 (6.6)

35.4 (7.9)

35.4 (7.7)

 Median (IQR)

33.0 (11.0)

35.0 (10.0)

35.0 (10.0)

 Range

21.0 - 50.0

21.0 - 62.0

20.0 - 69.0

Sex

 F

79 (58.96%)

77 (57.46%)

66 (50.00%)

 M

51 (38.06%)

55 (41.04%)

60 (45.45%)

 U

3 (2.24%)

2 (1.49%)

4 (3.03%)

 UNDIFFERENTIATED

1 (0.75%)

0 (0.00%)

2 (1.52%)

Country

 CHN

74 (55.22%)

81 (60.45%)

64 (48.48%)

 USA

10 (7.46%)

13 (9.70%)

17 (12.88%)

 BRA

13 (9.70%)

7 (5.22%)

10 (7.58%)

 PAK

12 (8.96%)

9 (6.72%)

10 (7.58%)

 NGA

8 (5.97%)

7 (5.22%)

11 (8.33%)

 RUS

5 (3.73%)

8 (5.97%)

6 (4.55%)

 JPN

5 (3.73%)

4 (2.99%)

9 (6.82%)

 GBR

4 (2.99%)

3 (2.24%)

2 (1.52%)

 CAN

3 (2.24%)

2 (1.49%)

3 (2.27%)

 CHE

0 (0.00%)

0 (0.00%)

0 (0.00%)

Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY

+

x.x: Study Subject Data

x.x.x: Demographic Characteristics

Table x.x.x.x: Demographic Characteristics - Full Analysis Set

A: Drug X
(N=134)

B: Placebo
(N=134)

C: Combination
(N=132)

Age

 Mean (SD)

33.8 (6.6)

35.4 (7.9)

35.4 (7.7)

 Median (IQR)

33.0 (11.0)

35.0 (10.0)

35.0 (10.0)

 Range

21.0 - 50.0

21.0 - 62.0

20.0 - 69.0

Sex

 F

79 (58.96%)

77 (57.46%)

66 (50.00%)

 M

51 (38.06%)

55 (41.04%)

60 (45.45%)

 U

3 (2.24%)

2 (1.49%)

4 (3.03%)

 UNDIFFERENTIATED

1 (0.75%)

0 (0.00%)

2 (1.52%)

Country

 CHN

74 (55.22%)

81 (60.45%)

64 (48.48%)

 USA

10 (7.46%)

13 (9.70%)

17 (12.88%)

 BRA

13 (9.70%)

7 (5.22%)

10 (7.58%)

 PAK

12 (8.96%)

9 (6.72%)

10 (7.58%)

 NGA

8 (5.97%)

7 (5.22%)

11 (8.33%)

 RUS

5 (3.73%)

8 (5.97%)

6 (4.55%)

 JPN

5 (3.73%)

4 (2.99%)

9 (6.82%)

 GBR

4 (2.99%)

3 (2.24%)

2 (1.52%)

 CAN

3 (2.24%)

2 (1.49%)

3 (2.27%)

 CHE

0 (0.00%)

0 (0.00%)

0 (0.00%)

Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY

4.1.5 tables

@@ -1207,25 +1207,25 @@

4.1.5 tables
useGroupLabels(tab, indent = " ")

- +
- +
@@ -1642,7 +1642,7 @@

4.1.6 tidytlg

Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY

[table x.x.x.x.html][/home/runner/work/_temp/80b9dcaf-197d-4f31-83d0-e731f0c01c9a] 06OCT2023, 01:15
[table x.x.x.x.html][/home/runner/work/_temp/dbc50335-555d-4c9d-8c49-eaade0bcc058] 03NOV2023, 00:16
@@ -1809,23 +1809,23 @@

4.1.7 tfrmt ) ) %>% print_to_gt(demog_ard) -
- - + + + + + + @@ -2261,9 +2268,9 @@

4.1.7 tfrmt

- - - + + + @@ -2281,9 +2288,9 @@

4.1.7 tfrmt 21.0 - 62.0

- - - + + + @@ -2293,9 +2300,9 @@

4.1.7 tfrmt 52 (38.8%)

- - - + + + @@ -2648,23 +2655,23 @@

4.2.3 gt indent = 3 ) -
- @@ -3295,25 +3302,25 @@

4.2.4 tablesuseGroupLabels(tab, indent = " ", extraLines = 1)

-

x.x: Study Subject Data
x.x.x: Demographic Characteristics. + + Table x.x.x.x: Demographic Characteristics - Full Analysis Set
A: Drug X
Age (years)



n 134 134 20.0 - 69.0
Sex



F 79 (59.0%) 82 (61.2%) 62 (47.0%)
Country



CHN 74 (55.2%) 81 (60.4%)
+
- +
@@ -3930,7 +3937,7 @@

4.2.5 flextable top = FALSE) |> hline(i = 1, part = "header", border = fp_border_default(width = 0)) -

A: Drug X

B: Placebo

C: Combination

(N=134)

(N=134)

(N=132)

Patients with at least one event

122 (91.04%)

123 (91.79%)

120 (90.91%)

Total number of events

609

622

703

cl A.1

 Patients with at least one event

78 (58.21%)

75 (55.97%)

89 (66.42%)

 Total number of events

132

130

160

 dcd A.1.1.1.1

50 (37.31%)

45 (33.58%)

63 (47.01%)

 dcd A.1.1.1.2

48 (35.82%)

48 (35.82%)

50 (37.31%)

cl B.1

 Patients with at least one event

47 (35.07%)

49 (36.57%)

43 (32.09%)

 Total number of events

56

60

62

 dcd B.1.1.1.1

47 (35.07%)

49 (36.57%)

43 (32.09%)

cl B.2

 Patients with at least one event

79 (58.96%)

74 (55.22%)

85 (63.43%)

 Total number of events

129

138

143

 dcd B.2.1.2.1

49 (36.57%)

44 (32.84%)

52 (38.81%)

 dcd B.2.2.3.1

48 (35.82%)

54 (40.30%)

51 (38.06%)

cl C.1

 Patients with at least one event

43 (32.09%)

46 (34.33%)

43 (32.09%)

 Total number of events

55

63

64

 dcd C.1.1.1.3

43 (32.09%)

46 (34.33%)

43 (32.09%)

cl C.2

 Patients with at least one event

35 (26.12%)

48 (35.82%)

55 (41.04%)

 Total number of events

48

53

65

 dcd C.2.1.2.1

35 (26.12%)

48 (35.82%)

55 (41.04%)

cl D.1

 Patients with at least one event

79 (58.96%)

67 (50.00%)

80 (59.70%)

 Total number of events

127

106

135

 dcd D.1.1.1.1

50 (37.31%)

42 (31.34%)

51 (38.06%)

 dcd D.1.1.4.2

48 (35.82%)

42 (31.34%)

50 (37.31%)

cl D.2

 Patients with at least one event

47 (35.07%)

58 (43.28%)

57 (42.54%)

 Total number of events

62

72

74

 dcd D.2.1.5.3

47 (35.07%)

58 (43.28%)

57 (42.54%)

+

A: Drug X

B: Placebo

C: Combination

(N=134)

(N=134)

(N=132)

Patients with at least one event

122 (91.04%)

123 (91.79%)

120 (90.91%)

Total number of events

609

622

703

cl A.1

 Patients with at least one event

78 (58.21%)

75 (55.97%)

89 (66.42%)

 Total number of events

132

130

160

 dcd A.1.1.1.1

50 (37.31%)

45 (33.58%)

63 (47.01%)

 dcd A.1.1.1.2

48 (35.82%)

48 (35.82%)

50 (37.31%)

cl B.1

 Patients with at least one event

47 (35.07%)

49 (36.57%)

43 (32.09%)

 Total number of events

56

60

62

 dcd B.1.1.1.1

47 (35.07%)

49 (36.57%)

43 (32.09%)

cl B.2

 Patients with at least one event

79 (58.96%)

74 (55.22%)

85 (63.43%)

 Total number of events

129

138

143

 dcd B.2.1.2.1

49 (36.57%)

44 (32.84%)

52 (38.81%)

 dcd B.2.2.3.1

48 (35.82%)

54 (40.30%)

51 (38.06%)

cl C.1

 Patients with at least one event

43 (32.09%)

46 (34.33%)

43 (32.09%)

 Total number of events

55

63

64

 dcd C.1.1.1.3

43 (32.09%)

46 (34.33%)

43 (32.09%)

cl C.2

 Patients with at least one event

35 (26.12%)

48 (35.82%)

55 (41.04%)

 Total number of events

48

53

65

 dcd C.2.1.2.1

35 (26.12%)

48 (35.82%)

55 (41.04%)

cl D.1

 Patients with at least one event

79 (58.96%)

67 (50.00%)

80 (59.70%)

 Total number of events

127

106

135

 dcd D.1.1.1.1

50 (37.31%)

42 (31.34%)

51 (38.06%)

 dcd D.1.1.4.2

48 (35.82%)

42 (31.34%)

50 (37.31%)

cl D.2

 Patients with at least one event

47 (35.07%)

58 (43.28%)

57 (42.54%)

 Total number of events

62

72

74

 dcd D.2.1.5.3

47 (35.07%)

58 (43.28%)

57 (42.54%)

4.2.6 tidytlg

@@ -4055,7 +4062,7 @@

4.2.6 tidytlg
dcd D.2.1.5.3

47 (35.1%)58 (43.3%)57 (43.2%)
[table x.x.x.x.html][/home/runner/work/_temp/80b9dcaf-197d-4f31-83d0-e731f0c01c9a] 06OCT2023, 01:15
[table x.x.x.x.html][/home/runner/work/_temp/dbc50335-555d-4c9d-8c49-eaade0bcc058] 03NOV2023, 00:16
@@ -4155,23 +4162,23 @@

4.2.7 tfrmt ) |> print_to_gt(ae_ard) -
- @@ -4625,11 +4632,11 @@

4.2.7 tfrmt703 cl A.1 +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
Patients with at least one event 78 (58.2%) @@ -4660,11 +4667,11 @@

4.2.7 tfrmt 50 (37.9%) cl B.1 +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
Patients with at least one event 47 (35.1%) @@ -4688,11 +4695,11 @@

4.2.7 tfrmt 43 (32.6%) cl B.2 +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
Patients with at least one event 79 (59.0%) @@ -4723,11 +4730,11 @@

4.2.7 tfrmt 51 (38.6%) cl C.1 +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
Patients with at least one event 43 (32.1%) @@ -4751,11 +4758,11 @@

4.2.7 tfrmt 43 (32.6%) cl C.2 +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
Patients with at least one event 35 (26.1%) @@ -4779,11 +4786,11 @@

4.2.7 tfrmt 55 (41.7%) cl D.1 +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
Patients with at least one event 79 (59.0%) @@ -4814,11 +4821,11 @@

4.2.7 tfrmt 50 (37.9%) cl D.2 +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
Patients with at least one event 47 (35.1%) @@ -5380,23 +5387,23 @@

4.3.5 gt page.header.use_tbl_headings = TRUE, page.footer.use_tbl_notes = TRUE)

-
- @@ -5861,15 +5868,15 @@

4.3.5 gt4 ( 3.0) 14 (10.6) Hazard ratio - +
1.5 1.1 95% confidence interval - +
[ 1.1, 1.9] [ 0.8, 1.5] p-value (one-sided stratified log rank) - +
0.0208 0.4619 Time to first serious adverse event (a) @@ -6007,25 +6014,25 @@

4.3.6 tables indent = " ")

- +
- +
@@ -6246,7 +6253,7 @@

4.3.7 flextable ) |> hline(i = 1, part = "header", border = fp_border_default(width = 0)) -

A: Drug X

B: Placebo

C: Combination

(N=134)

(N=134)

(N=132)

Subjects with serious adverse events

89 (66.42%)

123 (91.79%)

88 (66.67%)

Number of censored subjects

 Clinical Cut Off

10 (7.46%)

4 (2.99%)

14 (10.61%)

 Completion or Discontinuation

13 (9.70%)

3 (2.24%)

16 (12.12%)

 End of AE Reporting Period

22 (16.42%)

4 (2.99%)

14 (10.61%)

Hazard ratio

1.5

1.1

95% confidence interval

(1.1, 1.9)

(0.8, 1.5)

p-value (one-sided stratified log rank)

0.0208

0.4619

Time to first serious adverse event

 Median (years)

0.39

0.37

0.26

 95% confidence interval

[0.23, 0.60]

[0.25, 0.46]

[0.18, 0.34]

 Min, Max

0.00, 3.00

0.00, 3.00

0.00, 3.00

+

A: Drug X

B: Placebo

C: Combination

(N=134)

(N=134)

(N=132)

Subjects with serious adverse events

89 (66.42%)

123 (91.79%)

88 (66.67%)

Number of censored subjects

 Clinical Cut Off

10 (7.46%)

4 (2.99%)

14 (10.61%)

 Completion or Discontinuation

13 (9.70%)

3 (2.24%)

16 (12.12%)

 End of AE Reporting Period

22 (16.42%)

4 (2.99%)

14 (10.61%)

Hazard ratio

1.5

1.1

95% confidence interval

(1.1, 1.9)

(0.8, 1.5)

p-value (one-sided stratified log rank)

0.0208

0.4619

Time to first serious adverse event

 Median (years)

0.39

0.37

0.26

 95% confidence interval

[0.23, 0.60]

[0.25, 0.46]

[0.18, 0.34]

 Min, Max

0.00, 3.00

0.00, 3.00

0.00, 3.00

4.3.8 tidytlg

@@ -6439,7 +6446,7 @@

4.3.8 tidytlgSource: ADTTE DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY

[table x.x.x.x.html][/home/runner/work/_temp/80b9dcaf-197d-4f31-83d0-e731f0c01c9a] 06OCT2023, 01:15
[table x.x.x.x.html][/home/runner/work/_temp/dbc50335-555d-4c9d-8c49-eaade0bcc058] 03NOV2023, 00:16
@@ -6610,23 +6617,23 @@

4.3.9 tfrmt) |> print_to_gt(model_ard) -
- @@ -7094,9 +7101,9 @@

4.3.9 tfrmt0.0416 0.9239 Time to first serious adverse event1 - - - +
+
+
Median (years) 0.39 0.37 @@ -7242,7 +7249,7 @@

4.4.3 flextable mk_par(i = 2, j = 1, part = "header", as_paragraph("Uses the adcm dataset from ", as_b("random.cdisc.data")))

-

Conmed Example

A: Drug X

B: Placebo

C: Combination

Uses the adcm dataset from random.cdisc.data

(N=134)

(N=134)

(N=132)

At Least One Concomittant Med

122 (91.0%)

123 (91.8%)

120 (90.9%)

medcl A

medname A_1/3

54 (40.3%)

49 (36.6%)

69 (52.3%)

medname A_2/3

53 (39.6%)

50 (37.3%)

56 (42.4%)

medname A_3/3

45 (33.6%)

54 (40.3%)

48 (36.4%)

medcl B

medname B_1/4

52 (38.8%)

57 (42.5%)

59 (44.7%)

medname B_2/4

52 (38.8%)

55 (41.0%)

56 (42.4%)

medname B_3/4

47 (35.1%)

47 (35.1%)

52 (39.4%)

medname B_4/4

50 (37.3%)

45 (33.6%)

55 (41.7%)

medcl C

medname C_1/2

51 (38.1%)

50 (37.3%)

56 (42.4%)

medname C_2/2

52 (38.8%)

58 (43.3%)

60 (45.5%)

+

Conmed Example

A: Drug X

B: Placebo

C: Combination

Uses the adcm dataset from random.cdisc.data

(N=134)

(N=134)

(N=132)

At Least One Concomittant Med

122 (91.0%)

123 (91.8%)

120 (90.9%)

medcl A

medname A_1/3

54 (40.3%)

49 (36.6%)

69 (52.3%)

medname A_2/3

53 (39.6%)

50 (37.3%)

56 (42.4%)

medname A_3/3

45 (33.6%)

54 (40.3%)

48 (36.4%)

medcl B

medname B_1/4

52 (38.8%)

57 (42.5%)

59 (44.7%)

medname B_2/4

52 (38.8%)

55 (41.0%)

56 (42.4%)

medname B_3/4

47 (35.1%)

47 (35.1%)

52 (39.4%)

medname B_4/4

50 (37.3%)

45 (33.6%)

55 (41.7%)

medcl C

medname C_1/2

51 (38.1%)

50 (37.3%)

56 (42.4%)

medname C_2/2

52 (38.8%)

58 (43.3%)

60 (45.5%)

4.4.4 gt

@@ -7345,23 +7352,23 @@

4.4.4 gt columns = 1 )

-
- @@ -7906,25 +7913,25 @@

4.4.5 tablesuseGroupLabels(rbind(heading, body), indent = " ")

- +
- +
@@ -8231,7 +8238,7 @@

4.4.6 tidytlg
medname C_2/2

52 (38.8%)58 (43.3%)60 (45.5%)
[table x.x.x.x.html][/home/runner/work/_temp/80b9dcaf-197d-4f31-83d0-e731f0c01c9a] 06OCT2023, 01:15
[table x.x.x.x.html][/home/runner/work/_temp/dbc50335-555d-4c9d-8c49-eaade0bcc058] 03NOV2023, 00:16
@@ -8311,23 +8318,23 @@

4.4.7 tfrmt ) |> print_to_gt(cm_ard) -
- @@ -8774,11 +8781,11 @@

4.4.7 tfrmt120 (90.9%) medcl A +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
medname A_1/3 54 (40.3%) @@ -8802,11 +8809,11 @@

4.4.7 tfrmt 48 (36.4%) medcl B +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
medname B_1/4 52 (38.8%) @@ -8837,11 +8844,11 @@

4.4.7 tfrmt 55 (41.7%) medcl C +N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_right" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
medname C_1/2 51 (38.1%) @@ -9089,23 +9096,23 @@

4.5.3 gt 1 ~ px(200) )

-
- @@ -9704,7 +9711,7 @@

4.5.4 flextable autofit() ft

-

A: Drug X
(N=134)

B: Placebo
(N=134)

C: Combination
(N=132)

Completed

68 (50.7%)

66 (49.3%)

73 (55.3%)

Ongoing

24 (17.9%)

28 (20.9%)

21 (15.9%)

Discontinued

 Adverse Event

3 (2.2%)

6 (4.5%)

5 (3.8%)

 Death

25 (18.7%)

23 (17.2%)

22 (16.7%)

  Adverse Event

9 (6.7%)

7 (5.2%)

10 (7.6%)

  Disease Progression

8 (6.0%)

6 (4.5%)

6 (4.5%)

  Lost to Follow Up

2 (1.5%)

2 (1.5%)

2 (1.5%)

  Missing

2 (1.5%)

3 (2.2%)

2 (1.5%)

  Post-Study Reporting of Death

1 (0.7%)

2 (1.5%)

1 (0.8%)

  Suicide

2 (1.5%)

2 (1.5%)

1 (0.8%)

  Unknown

1 (0.7%)

1 (0.7%)

 Lack of Efficacy

2 (1.5%)

2 (1.5%)

3 (2.3%)

 Physician Decision

2 (1.5%)

3 (2.2%)

2 (1.5%)

 Protocol Violation

5 (3.7%)

3 (2.2%)

4 (3.0%)

 Withdrawal by Parent/Guardian

4 (3.0%)

2 (1.5%)

1 (0.8%)

 Withdrawal by Subject

1 (0.7%)

1 (0.7%)

1 (0.8%)

+

A: Drug X
(N=134)

B: Placebo
(N=134)

C: Combination
(N=132)

Completed

68 (50.7%)

66 (49.3%)

73 (55.3%)

Ongoing

24 (17.9%)

28 (20.9%)

21 (15.9%)

Discontinued

 Adverse Event

3 (2.2%)

6 (4.5%)

5 (3.8%)

 Death

25 (18.7%)

23 (17.2%)

22 (16.7%)

  Adverse Event

9 (6.7%)

7 (5.2%)

10 (7.6%)

  Disease Progression

8 (6.0%)

6 (4.5%)

6 (4.5%)

  Lost to Follow Up

2 (1.5%)

2 (1.5%)

2 (1.5%)

  Missing

2 (1.5%)

3 (2.2%)

2 (1.5%)

  Post-Study Reporting of Death

1 (0.7%)

2 (1.5%)

1 (0.8%)

  Suicide

2 (1.5%)

2 (1.5%)

1 (0.8%)

  Unknown

1 (0.7%)

1 (0.7%)

 Lack of Efficacy

2 (1.5%)

2 (1.5%)

3 (2.3%)

 Physician Decision

2 (1.5%)

3 (2.2%)

2 (1.5%)

 Protocol Violation

5 (3.7%)

3 (2.2%)

4 (3.0%)

 Withdrawal by Parent/Guardian

4 (3.0%)

2 (1.5%)

1 (0.8%)

 Withdrawal by Subject

1 (0.7%)

1 (0.7%)

1 (0.8%)

4.5.5 tables

@@ -9764,25 +9771,25 @@

4.5.5 tables indent = " ")

- +
- +
@@ -10165,7 +10172,7 @@

4.5.6 tidytlg
UNKNOWN

1 (0.7%)1 (0.7%)0
[table x.x.x.x.html][/home/runner/work/_temp/80b9dcaf-197d-4f31-83d0-e731f0c01c9a] 06OCT2023, 01:15
[table x.x.x.x.html][/home/runner/work/_temp/dbc50335-555d-4c9d-8c49-eaade0bcc058] 03NOV2023, 00:16
@@ -10240,23 +10247,23 @@

4.5.7 tfrmt )|> print_to_gt(disp_ard) -
- @@ -10710,11 +10717,11 @@

4.5.7 tfrmt73 (55.3%) DISCONTINUED +N = 134" class="gt_row gt_left" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_left" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_left" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
ADVERSE EVENT 3 ( 2.2%) @@ -10724,11 +10731,11 @@

4.5.7 tfrmt 5 ( 3.8%) DEATH +N = 134" class="gt_row gt_left" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 134" class="gt_row gt_left" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
+N = 132" class="gt_row gt_left" style="text-align: left; white-space: pre-wrap; font-family: Courier, system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji'; border-top-width: 1px; border-top-style: solid; border-top-color: transparent; border-bottom-width: 1px; border-bottom-style: solid; border-bottom-color: transparent;">
ADVERSE EVENT 9 ( 6.7%) diff --git a/contributors.html b/contributors.html index bad595a..0be651a 100644 --- a/contributors.html +++ b/contributors.html @@ -6,7 +6,7 @@ A Contributors to this book | Tables in Clinical Trials with R - + @@ -23,7 +23,7 @@ - + @@ -55,7 +55,7 @@ - + @@ -830,9 +830,9 @@

3.1.1 gt35.0 35.0 Min - Max - - - +
+
+
Sex, n (%) @@ -878,23 +878,23 @@

3.1.1 gt ) )

-
- @@ -1352,9 +1352,9 @@

3.1.1 gt35.0 35.0 Min - Max - - - +
+
+
Sex, n (%) @@ -1454,14 +1454,14 @@

3.1.3 flextable as_flextable() z

-

SEX

A: Drug X

B: Placebo

C: Combination

F

32.8 (6.1)

34.2 (7.0)

35.2 (7.4)

M

35.2 (7.0)

37.3 (8.9)

35.7 (8.2)

+

SEX

A: Drug X

B: Placebo

C: Combination

F

32.8 (6.1)

34.2 (7.0)

35.2 (7.4)

M

35.2 (7.0)

37.3 (8.9)

35.7 (8.2)

The following shows how to add titles or notes:

Code 
z |>
   add_header_lines("hello world") |>
   add_footer_lines("bye bye world")
-

hello world

SEX

A: Drug X

B: Placebo

C: Combination

F

32.8 (6.1)

34.2 (7.0)

35.2 (7.4)

M

35.2 (7.0)

37.3 (8.9)

35.7 (8.2)

bye bye world

+

hello world

SEX

A: Drug X

B: Placebo

C: Combination

F

32.8 (6.1)

34.2 (7.0)

35.2 (7.4)

M

35.2 (7.0)

37.3 (8.9)

35.7 (8.2)

bye bye world

For Word output, users can prepend a table number that will auto-incremente.

Code 
docx_file <- "reports/flextable-title-01.docx"
@@ -1484,7 +1484,7 @@ 
3.1.3 flextable
footnote(z, i = c(1, 2, 2), j = c(1, 5, 7), 
          value = as_paragraph("hello world"), ref_symbols = "(1)")
-

SEX

A: Drug X

B: Placebo

C: Combination

F(1)

32.8 (6.1)

34.2 (7.0)

35.2 (7.4)

M

35.2 (7.0)

37.3 (8.9)(1)

35.7 (8.2)(1)

(1)hello world

+

SEX

A: Drug X

B: Placebo

C: Combination

F(1)

32.8 (6.1)

34.2 (7.0)

35.2 (7.4)

M

35.2 (7.0)

37.3 (8.9)(1)

35.7 (8.2)(1)

(1)hello world

3.1.4 tfrmt

@@ -1537,23 +1537,23 @@

3.1.4 tfrmt print_mock_gt(tfrmt_spec, df)

-
- - + + + + + + @@ -1989,9 +1994,9 @@

3.1.4 tfrmt

- - - + + + @@ -2005,9 +2010,9 @@

3.1.4 tfrmt

- - - + + + @@ -2192,7 +2197,7 @@

3.1.6 tidytlgNote: N reflects non-missing values

- +
Demographic Table - All Patients
Cutoff Date: June 01, 2022. Arm B received a placebo.
Combination1
AGE2



label 1 xx (xx.x) xx (xx.x)
SEX



label 1 xx (xx.x) xx (xx.x)
[table01.html][/home/runner/work/_temp/80b9dcaf-197d-4f31-83d0-e731f0c01c9a] 06OCT2023, 01:15
[table01.html][/home/runner/work/_temp/dbc50335-555d-4c9d-8c49-eaade0bcc058] 03NOV2023, 00:16

To programmatically incorporate titles and footnotes into each table program, users can create an excel file called titles.xls (see below snapshot) with the columns of "TABLE ID","IDENTIFIER","TEXT". In the gentlg() function call, users just need to provide the argument of title_file for specifying the location of titles.xls. Then the title and footnotes corresponding to the table ID will be automatically included in the table output. Users need to make sure the correct table ID is used for the file argument of the gentlg() function call.

@@ -2227,13 +2232,13 @@

3.2.1 flextable caption = "a caption", autonum = officer::run_autonum(seq_id = "tab", bkm = "flextable-label"))

-
+
-
Table 3.2: a caption

speed

dist

4

2

4

10

7

4

7

22

8

16

9

10

+

speed

dist

4

2

4

10

7

4

7

22

8

16

9

10

In bookdown, use the syntax \@ref(tab:flextable-label) to create a linked reference to the table. Here is an example of a reference: 3.2.

With Quarto, the R chunk code should be transformed as:

diff --git a/index.html b/index.html index c444f0e..1a5f1af 100644 --- a/index.html +++ b/index.html @@ -6,7 +6,7 @@ Tables in Clinical Trials with R - + @@ -23,7 +23,7 @@ - + @@ -55,7 +55,7 @@ - +